| Citation: | Li Tong-Du, . The Determination of ER, PR and β2-microglobulin Expression of Bladder Cancer Tissue In The Diagnosis And Prognosis Estimation of Bladder Tumor[J]. Cancer Research on Prevention and Treatment, 1996, 23(5): 265-267. |
|
1 Kiang DT. et al. JAMA, 1977. 238:32.
|
|
2 Linsalata M. Sond Gastroenterol, 1994, 29(1):67.
|
|
3 Papac R, et al. Eur J Cancer. 1993, 29A(7):997.
|
|
4 Schomburg A. Eur J Cancer, 1993, 29A(5):737.
|
|
5 Marly ML, et al. Br J Dermatol, 1981. 104:507.
|
|
6 Van dan Zugh-HF. et al. Br J Cancer. 1987. 55(2):125.
|
| [1] | JIAO Juying, ZHOU Lei, LIN Bo, ZENG Jingyi, XU Weijie. Basic Research Progress and Prospect of Antibody-Drug Conjugate in Treatment of Pancreatic Cancer[J]. Cancer Research on Prevention and Treatment, 2025, 52(9): 787-791. DOI: 10.3971/j.issn.1000-8578.2025.25.0293 |
| [2] | YE Hunan, SHEN Yulan, LI Jiaying, ZHOU Huanhuan, ZHANG Fanrong, WANG Xiaojia. Research Advancements of Antibody-Drug Conjugates in Breast Cancer at 2024 ASCO Annual Meeting[J]. Cancer Research on Prevention and Treatment, 2025, 52(3): 185-192. DOI: 10.3971/j.issn.1000-8578.2025.24.0999 |
| [3] | MA Yiwen, XU Junnan, SUN Tao. Research Progress in Treatment of HR-Positive/HER 2-Low Advanced Breast Cancer: Interpretation of Breast Cancer Research Hotspots in 2024 ASCO[J]. Cancer Research on Prevention and Treatment, 2025, 52(2): 98-102. DOI: 10.3971/j.issn.1000-8578.2025.24.1033 |
| [4] | JIA Yanli, LI Xiaoyu, FAN Houwu, DUAN Wenqing, HU Lixia, ZHOU Jian, RAN Fengming, DONG Shuang. Research Progress on Mechanisms and Optimization Methods for Toxicity Induced by Antibody–Drug Conjugates[J]. Cancer Research on Prevention and Treatment, 2024, 51(7): 606-612. DOI: 10.3971/j.issn.1000-8578.2024.23.1373 |
| [5] | HAN Jing, CHEN Yarui, WANG Song, GUAN Quanlin. Research Progress of Antibody-drug Conjugates in Small-cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2023, 50(11): 1139-1144. DOI: 10.3971/j.issn.1000-8578.2023.23.0447 |
| [6] | CHEN Yarui, WANG Jiangtao, GUAN Quanlin, JI Wei, JIAO Fuzhi. Research Progress of Antibody-drug Conjugates in Advanced Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(8): 855-860. DOI: 10.3971/j.issn.1000-8578.2022.21.1466 |
| [7] | ZHENG Fangchao, DU Feng, LIU Haolin, WANG Xue, YUE Jian, YUAN Peng. Recent Progress of Palbociclib in Treatment of HR+/HER2- Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(7): 703-708. DOI: 10.3971/j.issn.1000-8578.2022.22.0220 |
| [8] | LI Zhensheng, KONG Deyou, DUAN Xuejuan, SHEN Xiaofei, SHEN Dongxing, ZHANG Jun. Effects of Whole-brain Radiotherapy Combined with Targeted Therapy on Improving Survival of HER2-positive Breast Cancer Patients with Brain Metastases[J]. Cancer Research on Prevention and Treatment, 2018, 45(11): 917-922. DOI: 10.3971/j.issn.1000-8578.2018.18.0324 |
| [9] | Zhou Xin, Wu Chengyi. Relationship of CD44+/CD24-/low with Responsiveness of Breast Cancer to Anthracycline-based Chemotherapy[J]. Cancer Research on Prevention and Treatment, 2012, 39(08): 966-969. DOI: 10.3971/j.issn.1000-8578.2012.08.021 |
| [10] | FU Qiang, YU Shiying, XU Sanpeng. Prognostic Correlation of HER2 Over2expressions in Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2008, 35(S1): 9-11. DOI: 10.3971/j.issn.1000-8578.986 |